Comparatively, the myeloid leukemia cell line MOLM14 (harboring a heterozygous FLT3 ITD mutation), which is a well-established model to test FLT3 tyrosine kinase inhibitors [19-21], was treated with crenolanib. This evidence concerns the gene FLT3 and myeloid leukemia.